ChristinaSeungBaikMD

Oncology • Seattle, WA

Instructor, Medicine, University of Washington School of Medicine

Join to view full profile

Dr. Baik is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Baik's full profile

Already have an account?

Office
825 Eastlake Ave E
Seattle, WA 98109
Phone+1 206-543-6420

Education & Training

Tufts Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Brown UniversityResidency, Internal Medicine, 2002 - 2005
University of Rochester School of Medicine and DentistryClass of 2002

Certifications & Licensure

WA State Medical License 2011 - 2025
American Board of Internal Medicine Medical Oncology

Clinical Trials

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer Start of enrollment: 2012 Dec 02
Completed
Phase 2
Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
No longer available
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

247 citations
Dabrafenib plus trametinib in patients with previously untreated BRAF-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
David Planchard, Egbert F Smit, Harry J M Groen, Julien Mazieres, Benjamin Besse
The Lancet. Oncology. 2017-10-01
520 citations
An open-label phase 2 trial of dabrafenib plus trametinib in patients with previously treated BRAF V600E–mutant metastatic non-small cell lung cancer
David Planchard, Benjamin Besse, Harry J.M. Groen, Pierre-Jean Souquet, Elisabeth Quoix
The Lancet. Oncology. 2016-07-01
2 citations
Systemic Treatment Patterns and Outcomes in Patients With EGFR Mutated Non-small Cell Lung Cancer and Leptomeningeal Disease.
Cristina M Merkhofer, Boryana Eastman, Isabella Densmore, Lia M Halasz, Tresa McGranahan
Clinical Lung Cancer. 2022-07-01

Journal Articles

Trastuzumab Emtansine (T-dM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety and Biomarkers
Augusto Villegas, Christina S Baik, Clinical Cancer Research

Press Mentions

Seeking to Expand Targeted Therapy for Lung CancerAugust 9th, 2021
Clinical Oncology Findings from Seattle Cancer Care Alliance (SCCA) Clinicians to Be Featured at the 2021 ASCO Annual MeetingJune 3rd, 2021
Phase III Trial Reports Chemoimmunotherapy Is Superior to Chemotherapy Alone in Malignant Pleural MesotheliomaSeptember 7th, 2023
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Other Languages

Korean